Bionik Laboratories Corp. BNKL
OTC PK
| 03/31/2023 | 12/31/2022 | 09/30/2022 | 06/30/2022 | 03/31/2022 | |
|---|---|---|---|---|---|
| Net Income | 52.48% | 45.62% | 4.29% | 5.99% | -- |
| Total Depreciation and Amortization | -38.40% | -64.64% | -59.82% | -52.14% | -- |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -91.99% | -90.84% | -19.52% | -17.30% | -- |
| Change in Net Operating Assets | 621.65% | 278.73% | -85.73% | -62.70% | -- |
| Cash from Operations | 18.33% | 1.10% | -56.80% | -29.86% | -- |
| Capital Expenditure | 29.60% | 36.00% | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -1,690.40% | -1,684.00% | -- | -- | -- |
| Total Debt Issued | -63.06% | -76.34% | -88.55% | 214.29% | -- |
| Total Debt Repaid | -- | 200.00% | -- | -- | -- |
| Issuance of Common Stock | -- | -- | -- | -- | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -63.06% | -76.31% | -88.55% | 214.29% | -- |
| Foreign Exchange rate Adjustments | 58.33% | 55.71% | 59.49% | -776.92% | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -213.08% | -208.50% | -227.83% | 142.29% | -- |